Technology and Innovation
by Jenna Ogilvie | Sep 6, 2016 | Discussion Paper, Perspectives
In this Perspective, the authors aim to facilitate the growth of learning health environments by highlighting strategies and examples of operational and research collaborations within delivery system settings in the United States. Informed by empirical data,...
by Jenna Ogilvie | Jul 20, 2016 | Discussion Paper, Perspectives
Problem Statement Declining or stagnant research and development (R&D) productivity has led many observers to argue that the current paradigm for drug discovery and development requires disruptive innovation (The term “disruptive innovation” is...
by Jenna Ogilvie | Feb 2, 2016 | Commentary, Perspectives
In early 2015, President Obama announced a $215 million investment in the 2016 budget to revolutionize health improvement efforts and disease treatment. The Precision Medicine Initiative (PMI) is a new model of patient-powered research using big data to...
by Laura DeStefano | Sep 11, 2015 | Discussion Paper, Perspectives
Abstract Despite the fact that they have gone through a rigorous approval process, uncertainty about newly approved drugs always exists. The uncertainty is amplified when drugs are approved on preliminary or interim evidence (i.e., accelerated approval) or on...
by Laura DeStefano | Jun 23, 2015 | Discussion Paper, Perspectives
ABSTRACT Background: Despite greater spending on health care and biomedical research, the United States has poorer health outcomes than competitive nations. Information is needed on the potential impact of interventions to better guide resources allocation. Objective:...
by Jenna Ogilvie | Jun 22, 2015 | Discussion Paper, Perspectives
The types of evidence needed to support the use of genome sequencing in the clinic varies by stakeholder and circumstance. In this IOM series, seven individually authored commentaries explore this important issue, discussing the challenges involved in and...
by Jenna Ogilvie | Apr 16, 2015 | Discussion Paper, Perspectives
The first round of awards in the State Innovation Models (SIMs) Initiative by the Center for Medicare and Medicaid Innovation (CMMI) created a wave of excitement and a sense of opportunity knocking. We previously wrote that “we believe that the SIMs developed...
by Jenna Ogilvie | Feb 26, 2015 | Commentary, Perspectives
The types of evidence needed to support the use of genome sequencing in the clinic varies by stakeholder and circumstance. In this IOM series, seven individually authored commentaries explore this important issue, discussing the challenges involved in and...
by Jenna Ogilvie | Feb 19, 2015 | Discussion Paper, Perspectives
The types of evidence needed to support the use of genome sequencing in the clinic varies by stakeholder and circumstance. In this IOM series, seven individually authored commentaries explore this important issue, discussing the challenges involved in and...
by Jenna Ogilvie | Feb 12, 2015 | Discussion Paper, Perspectives
The types of evidence needed to support the use of genome sequencing in the clinic varies by stakeholder and circumstance. In this IOM series, seven individually authored commentaries explore this important issue, discussing the challenges involved in and...
Page 4 of 6« First«...23456»
